Manhattan Scients Stock Beta
| MHTX Stock | USD 0.0009 0.0001 12.50% |
Manhattan Scients fundamentals help investors to digest information that contributes to Manhattan Scients' financial success or failures. It also enables traders to predict the movement of Manhattan Pink Sheet. The fundamental analysis module provides a way to measure Manhattan Scients' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Manhattan Scients pink sheet.
Manhattan |
Manhattan Scients Company Beta Analysis
Manhattan Scients' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Manhattan Scients Beta | 1.74 |
Most of Manhattan Scients' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Manhattan Scients is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Manhattan Scients has a Beta of 1.7357. This is 101.83% higher than that of the Biotechnology sector and 66.89% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Manhattan Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Manhattan Scients' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Manhattan Scients could also be used in its relative valuation, which is a method of valuing Manhattan Scients by comparing valuation metrics of similar companies.Manhattan Scients is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Manhattan Scients will likely underperform.
Manhattan Fundamentals
| Return On Equity | -2.51 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (13.38) % | |||
| Current Valuation | 4.33 M | |||
| Shares Outstanding | 559.28 M | |||
| Shares Owned By Insiders | 18.63 % | |||
| Shares Owned By Institutions | 0.30 % | |||
| Price To Earning | 1.35 X | |||
| Price To Book | 15.64 X | |||
| Price To Sales | 99.55 X | |||
| Revenue | 50 K | |||
| Gross Profit | 50 K | |||
| EBITDA | (3.61 M) | |||
| Net Income | (3.64 M) | |||
| Cash And Equivalents | 386 K | |||
| Total Debt | 143 K | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 0.26 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (421 K) | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 0.25 | |||
| Beta | 1.74 | |||
| Market Capitalization | 4.5 M | |||
| Total Asset | 3.45 M | |||
| Retained Earnings | (74.66 M) | |||
| Working Capital | 4.08 M | |||
| Current Asset | 5.36 M | |||
| Current Liabilities | 1.29 M | |||
| Z Score | -12.9 | |||
| Net Asset | 3.45 M |
About Manhattan Scients Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Manhattan Scients's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Manhattan Scients using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Manhattan Scients based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Manhattan Pink Sheet Analysis
When running Manhattan Scients' price analysis, check to measure Manhattan Scients' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Manhattan Scients is operating at the current time. Most of Manhattan Scients' value examination focuses on studying past and present price action to predict the probability of Manhattan Scients' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Manhattan Scients' price. Additionally, you may evaluate how the addition of Manhattan Scients to your portfolios can decrease your overall portfolio volatility.